dotData Announces dotData Ops: A Revolution in MLOps
dotData Ops democratizes enterprise AI and ML, empowering BI & Analytics professionals with streamlined data,…
News
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
– Board of Director appointments follow the Company’s recent launch and $200 million Series A…
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
– Board of Director appointments follow the Company’s recent launch and $200 million Series A…
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out…
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out…
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC….
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) — BIOXYTRAN, INC….
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced…
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced…
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin…
Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin…
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”)…
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”)…
Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections
Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot…
Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections
Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot…
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics…
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics…
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (“NKGen” or the…
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (“NKGen” or the…
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of…